OCY Stock Overview
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Oncimmune Holdings plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.22 |
52 Week High | UK£0.45 |
52 Week Low | UK£0.15 |
Beta | 1.14 |
1 Month Change | -9.02% |
3 Month Change | -16.54% |
1 Year Change | -39.34% |
3 Year Change | -89.63% |
5 Year Change | -75.60% |
Change since IPO | -85.33% |
Recent News & Updates
Recent updates
Shareholder Returns
OCY | DE Biotechs | DE Market | |
---|---|---|---|
7D | 20.7% | 1.2% | 2.5% |
1Y | -39.3% | 34.7% | 7.0% |
Return vs Industry: OCY underperformed the German Biotechs industry which returned 37% over the past year.
Return vs Market: OCY underperformed the German Market which returned 7.3% over the past year.
Price Volatility
OCY volatility | |
---|---|
OCY Average Weekly Movement | 7.2% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OCY's share price has been volatile over the past 3 months.
Volatility Over Time: OCY's weekly volatility has decreased from 12% to 7% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Martin Gouldstone | https://www.oncimmune.com |
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.
Oncimmune Holdings plc Fundamentals Summary
OCY fundamental statistics | |
---|---|
Market cap | €18.17m |
Earnings (TTM) | -€7.18m |
Revenue (TTM) | €1.34m |
13.5x
P/S Ratio-2.5x
P/E RatioIs OCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OCY income statement (TTM) | |
---|---|
Revenue | UK£1.15m |
Cost of Revenue | UK£360.00k |
Gross Profit | UK£792.00k |
Other Expenses | UK£6.94m |
Earnings | -UK£6.15m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.083 |
Gross Margin | 68.75% |
Net Profit Margin | -533.94% |
Debt/Equity Ratio | 786.9% |
How did OCY perform over the long term?
See historical performance and comparison